United States Biotechnology & Medical Research

Septerna Inc (SEPN)

Track

Ticker: SEPN Exchange: NMS
Preparing chart...
Download chart Copy chart image Copy link Share to X Share


• Purchase • Sale • Planned purchase • Planned sale Net purchase Net sale Buy signal Sell signal Earnings
Upgrade for signal details

Upgrade to see score, net flow, insiders and context.

Upgrade to see full signal details →

Insider trades have triggered activity signals for Septerna Inc. Upgrade to see score, net flow, insiders and the full signal context.

Open in Activity Signals screener →
Top insiders
Trades
Proposed sale 12 Aug 2026
Value US$2,383,181.13 | Price 263.14 | Shares 96,642
Abbreviations B: Buy, S: Sell, PP: Planned purchase, PlS: Planned sale, PrS: Proposed sale, O: Option / Other
Notification date Transaction date B/S Transaction type Insider and/or position Nb. shares
Price
Value 		Number of shares Price Value Details
2026-08-12 2026-08-12 PrS Proposed sale
3.2
Third Rock Ventures V, L.P.

10% Stockholder

Large shareholder
96,642
263.14
US$2,383,181 		96,642 263.14 US$2,383,181
2026-08-11 2026-08-11 PrS Proposed sale
ELIZABETH P. BHATT

Officer

Officer
88,343
384.60
US$359,804 		88,343 384.60 US$359,804
2026-08-05 2026-08-03 PlS Planned sale
Long Daniel D.

SVP, Drug Discovery

Officer
13,706 +41.7%
453.43
US$2,567,391 		13,706 +41.7% 453.43 US$2,567,391
2026-08-05 2026-08-03 PlS Planned sale
Long Daniel D.

SVP, Drug Discovery

Officer
1,000 -1.0%
33.98
US$100,000 		1,000 -1.0% 33.98 US$100,000
2026-07-17 2026-07-15 PlS Planned sale
Bhatt Elizabeth

President and COO

Officer
4,000 -2.2%
33.99
US$135,974 		4,000 -2.2% 33.99 US$135,974
2026-07-15 2026-07-15 PrS Proposed sale
ELIZABETH P. BHATT

Officer

Officer
4,000
34.54
US$138,160 		4,000 34.54 US$138,160
2026-07-02 2026-07-01 PlS Planned sale
Long Daniel D.

SVP, Drug Discovery

Officer
1,233 -1.3%
34.81
US$42,926 		1,233 -1.3% 34.81 US$42,926
2026-07-02 2026-07-01 PlS Planned sale
Long Daniel D.

SVP, Drug Discovery

Officer
2,100 -2.1%
34.10
US$71,602 		2,100 -2.1% 34.10 US$71,602
2026-06-30 2026-06-29 PlS Planned sale
Shaikhly Samira

Chief People Officer

Officer
2,178 -73.3%
35.18
US$76,622 		2,178 -73.3% 35.18 US$76,622
2026-06-26 2026-06-26 PrS Proposed sale
JAE KIM

Officer

Officer
2,438
36.61
US$89,243 		2,438 36.61 US$89,243
2026-06-24 2026-06-22 PlS Planned sale
Long Daniel D.

SVP, Drug Discovery

Officer
7,000 -6.8%
35.97
US$251,781 		7,000 -6.8% 35.97 US$251,781
2026-06-24 2026-06-22 PlS Planned sale
Long Daniel D.

SVP, Drug Discovery

Officer
8,000 -7.2%
35.10
US$280,801 		8,000 -7.2% 35.10 US$280,801
2026-06-22 2026-06-22 PrS Proposed sale
DANIEL LONG

Officer

Officer
25,000
36.17
US$904,250 		25,000 36.17 US$904,250
2026-06-22 2026-06-22 PrS Proposed sale
DANIEL LONG

Officer

Officer
25,000
36.17
US$904,250 		25,000 36.17 US$904,250
2026-06-22 2026-06-22 PrS Proposed sale
JAE KIM

Officer

Officer
94,339
35.26
US$3,326,120 		94,339 35.26 US$3,326,120
2026-06-22 2026-06-22 PrS Proposed sale
JAE KIM

Officer

Officer
94,339
35.26
US$3,326,120 		94,339 35.26 US$3,326,120
2026-06-16 2026-06-12 PlS Planned sale
Shaikhly Samira

Chief People Officer

Officer
6,250 -88.7%
35.08
US$219,224 		6,250 -88.7% 35.08 US$219,224
2026-06-12 2026-06-12 PrS Proposed sale
SAMIRA SHAIKHLY

Officer

Officer
8,428
34.03
US$286,805 		8,428 34.03 US$286,805
2026-06-03 2026-06-01 PlS Planned sale
Shaikhly Samira

Chief People Officer

Officer
2,889 -78.5%
29.66
US$85,696 		2,889 -78.5% 29.66 US$85,696
2026-06-03 2026-06-01 PlS Planned sale
Shaikhly Samira

Chief People Officer

Officer
1,346 -26.8%
28.79
US$38,755 		1,346 -26.8% 28.79 US$38,755
2026-06-03 2026-06-01 PlS Planned sale
Shaikhly Samira

Chief People Officer

Officer
1,700 -25.3%
27.78
US$47,231 		1,700 -25.3% 27.78 US$47,231
2026-05-28 2026-05-26 PlS Planned sale
Shaikhly Samira

Chief People Officer

Officer
11,798 -93.7%
30.06
US$354,656 		11,798 -93.7% 30.06 US$354,656
2026-05-26 2026-05-26 PrS Proposed sale
SAMIRA SHAIKHLY

Officer

Officer
11,798
28.36
US$334,591 		11,798 28.36 US$334,591
2026-04-17 2026-04-15 PlS Planned sale
Bhatt Elizabeth

President and COO

Officer
326 -0.2%
25.86
US$8,431 		326 -0.2% 25.86 US$8,431
2026-04-17 2026-04-15 PlS Planned sale
Bhatt Elizabeth

President and COO

Officer
1,101 -0.6%
25.24
US$27,789 		1,101 -0.6% 25.24 US$27,789
2026-04-17 2026-04-15 PlS Planned sale
Bhatt Elizabeth

President and COO

Officer
2,573 -1.4%
23.76
US$61,124 		2,573 -1.4% 23.76 US$61,124
2026-03-04 2026-03-02 PlS Planned sale
Shaikhly Samira

Chief People Officer

Officer
66,363 -98.8%
28.14
US$1,867,342 		66,363 -98.8% 28.14 US$1,867,342
2026-03-04 2026-03-02 PlS Planned sale
Shaikhly Samira

Chief People Officer

Officer
4,090 -5.7%
27.51
US$112,496 		4,090 -5.7% 27.51 US$112,496
2026-03-02 2026-03-02 PrS Proposed sale
SAMIRA SHAIKHLY

Officer

Officer
76,388
29.02
US$2,216,780 		76,388 29.02 US$2,216,780
2026-02-20 2026-02-18 PlS Planned sale
Bhatt Elizabeth

President and COO

Officer
1,800 -1.0%
29.58
US$53,250 		1,800 -1.0% 29.58 US$53,250
2026-02-20 2026-02-18 PlS Planned sale
Bhatt Elizabeth

President and COO

Officer
2,200 -1.2%
28.46
US$62,611 		2,200 -1.2% 28.46 US$62,611
2026-02-18 2026-02-18 PrS Proposed sale
ELIZABETH BHATT

Officer

Officer
8,000
30.30
US$242,400 		8,000 30.30 US$242,400
2025-11-13 2025-11-10 PlS Planned sale
Long Daniel D.

SVP, Drug Discovery

Officer
3,501 -3.6%
18.06
US$63,223 		3,501 -3.6% 18.06 US$63,223
2025-11-10 2025-11-10 PrS Proposed sale
DANIEL DAVID LONG

Officer

Officer
3,501
18.06
US$63,223 		3,501 18.06 US$63,223
2025-03-10 2025-03-07 B Purchase
2.8
Ezekowitz Alan
Non-Executive Director
13,319 +12.8%
6.93
US$92,270 		13,319 +12.8% 6.93 US$92,270
2025-03-06 2025-03-06 B Purchase
2.8
Ezekowitz Alan
Non-Executive Director
41,355 +65.9%
6.00
US$248,130 		41,355 +65.9% 6.00 US$248,130
2025-03-06 2025-03-05 B Purchase
2.8
Ezekowitz Alan
Non-Executive Director
37,835 +151.9%
5.82
US$220,260 		37,835 +151.9% 5.82 US$220,260
2025-03-06 2025-03-04 B Purchase
2.8
Ezekowitz Alan
Non-Executive Director
7,491 +43.0%
6.35
US$47,544 		7,491 +43.0% 6.35 US$47,544
2025-02-27 2025-02-27 B Purchase
3.6
Labrucherie Gil M

Chief Financial Officer

Officer
3,718 +10.2%
5.85
US$21,750 		3,718 +10.2% 5.85 US$21,750
2025-02-27 2025-02-27 B Purchase
3.5
Finer Jeffrey

CEO and President

Executive Director
3,000 +0.4%
5.80
US$17,400 		3,000 +0.4% 5.80 US$17,400
2025-02-27 2025-02-26 B Purchase
3.5
Finer Jeffrey

CEO and President

Executive Director
4,000 +0.5%
5.70
US$22,796 		4,000 +0.5% 5.70 US$22,796
2025-02-27 2025-02-25 B Purchase
3.6
Labrucherie Gil M

Chief Financial Officer

Officer
6,282 +20.9%
5.59
US$35,116 		6,282 +20.9% 5.59 US$35,116
2025-02-27 2025-02-25 B Purchase
3.5
Finer Jeffrey

CEO and President

Executive Director
10,000 +1.3%
5.68
US$56,765 		10,000 +1.3% 5.68 US$56,765
2025-02-26 2025-02-24 B Purchase
3.6
Third Rock Ventures VI, L.P.
Large shareholder
18,861 +0.4%
6.00
US$113,147 		18,861 +0.4% 6.00 US$113,147
2025-02-24 2025-02-21 B Purchase
3.6
Third Rock Ventures VI, L.P.
Large shareholder
427,668 +11.4%
5.94
US$2,540,348 		427,668 +11.4% 5.94 US$2,540,348
2025-02-21 2025-02-21 B Purchase
3.6
Labrucherie Gil M

Chief Financial Officer

Officer
5,000 +20.0%
5.85
US$29,250 		5,000 +20.0% 5.85 US$29,250
2025-02-24 2025-02-20 B Purchase
3.6
Third Rock Ventures VI, L.P.
Large shareholder
612,674 +19.4%
5.92
US$3,627,030 		612,674 +19.4% 5.92 US$3,627,030
2025-02-21 2025-02-20 B Purchase
3.6
Labrucherie Gil M

Chief Financial Officer

Officer
14,500 +138.1%
5.88
US$85,234 		14,500 +138.1% 5.88 US$85,234
2025-02-21 2025-02-19 B Purchase
3.6
Labrucherie Gil M

Chief Financial Officer

Officer
10,500 +inf%
5.51
US$57,813 		10,500 +inf% 5.51 US$57,813
2024-10-30 2024-10-28 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
341,600 +30.2%
18.00
US$6,148,800 		341,600 +30.2% 18.00 US$6,148,800
2024-10-30 2024-10-28 B Purchase
2.9
RA CAPITAL MANAGEMENT, L.P.
Non-Executive Director Large shareholder
3,828,400 +225.8%
18.00
US$68,911,200 		3,828,400 +225.8% 18.00 US$68,911,200
2024-10-28 2024-10-28 B Purchase
3.2
Third Rock Ventures V, L.P.
Large shareholder
279,500 +9.7%
18.00
US$5,031,000 		279,500 +9.7% 18.00 US$5,031,000
2024-10-28 2024-10-28 B Purchase
3.2
Third Rock Ventures V, L.P.
Large shareholder
370,500 +6.3%
18.00
US$6,669,000 		370,500 +6.3% 18.00 US$6,669,000
Explore more

More insider trading research around Septerna Inc

More insider trades in United States
Similar Healthcare companies with insider activity
More Pharmaceuticals & Medical Research companies with insider activity
More Biotechnology & Medical Research companies with insider activity
Insider trading in North America